Florian Castet1,2, Enrique Alanya3, Noemi Vidal4, Cristina Izquierdo2,5, Carlos Mesia1,2, François Ducray5,6, Miguel Gil-Gil1,2, Jordi Bruna7. 1. Medical Oncology Department, Institut Català D'Oncologia L'Hospitalet, Barcelona, Spain. 2. Unit of Neuro-Oncology, Hospital Universitari de Bellvitge-Institut Català D'Oncologia L'Hospitalet, IDIBELL (Oncobell Program), Feixa Llarga s/n, 08907, Barcelona, Spain. 3. Medical Oncology and Radiotherapy Department, Edgardo Rebagliati Martins National Hospital - EsSalud, Lima, Peru. 4. Pathology Department, Hospital Universitari de Bellvitge, Barcelona, Spain. 5. Groupe Hospitalier Est, Service de Neuro-Oncologie, Hospices Civils de Lyon, Lyon, France. 6. Department of Cancer Cell Plasticity, Cancer Research Centre of Lyon, INSERM U1052, CNRS UMR5286, Lyon, France. 7. Unit of Neuro-Oncology, Hospital Universitari de Bellvitge-Institut Català D'Oncologia L'Hospitalet, IDIBELL (Oncobell Program), Feixa Llarga s/n, 08907, Barcelona, Spain. 35078jbe@comb.cat.
Abstract
BACKGROUND: Contrast enhancement (CE) is found in 10-60% of low-grade gliomas. Its prognostic significance is controversial, and its correlation with IDH mutations and 1p/19q codeletion is elusive. The aim of this study is to investigate whether CE is associated with molecular characteristics of low-grade gliomas and uncover its prognostic value. MATERIALS AND METHODS: All confirmed histological cases of low-grade gliomas diagnosed at our institution between years 2000-2016 were reviewed (n = 102). Spinal and brainstem localization, only-biopsied tumours with ring-like enhancement and incomplete medical records were excluded. RESULTS: Mean age was 42 years ( ± 13.9 years), and 63.6% were male. The median follow-up time was 79.8 months. CE was present on 25% of preoperative MRI, and 25% of patients were considered high-risk according to Pignatti score. Most were astrocytomas (67%) and 87.2% were surgically removed. IDH mutation was found in 64.6% of tumour samples, and 18.8% had a 1p/19q codeletion. No subgroup differences were observed according to CE except for presurgical performance status and postoperative chemotherapy. IDH status and 1p/19q codeletion were evenly distributed. On univariate analysis, age, size > 6 cm, CE, extent of resection, Pignatti score, IDH mutation and 1p/19q codeletion were significantly associated to OS. On multivariate analysis, only CE and IDH status were independently associated to OS. CE remained a significant prognostic factor in IDH-mutant non-codeleted tumours when analysed by tumour subtype. CONCLUSION: CE in low-grade gliomas provides prognostic information in IDH-mutant non-codeleted tumours, although its meaning remains uncertain in IDH-wildtype gliomas.
BACKGROUND: Contrast enhancement (CE) is found in 10-60% of low-grade gliomas. Its prognostic significance is controversial, and its correlation with IDH mutations and 1p/19q codeletion is elusive. The aim of this study is to investigate whether CE is associated with molecular characteristics of low-grade gliomas and uncover its prognostic value. MATERIALS AND METHODS: All confirmed histological cases of low-grade gliomas diagnosed at our institution between years 2000-2016 were reviewed (n = 102). Spinal and brainstem localization, only-biopsied tumours with ring-like enhancement and incomplete medical records were excluded. RESULTS: Mean age was 42 years ( ± 13.9 years), and 63.6% were male. The median follow-up time was 79.8 months. CE was present on 25% of preoperative MRI, and 25% of patients were considered high-risk according to Pignatti score. Most were astrocytomas (67%) and 87.2% were surgically removed. IDH mutation was found in 64.6% of tumour samples, and 18.8% had a 1p/19q codeletion. No subgroup differences were observed according to CE except for presurgical performance status and postoperative chemotherapy. IDH status and 1p/19q codeletion were evenly distributed. On univariate analysis, age, size > 6 cm, CE, extent of resection, Pignatti score, IDH mutation and 1p/19q codeletion were significantly associated to OS. On multivariate analysis, only CE and IDH status were independently associated to OS. CE remained a significant prognostic factor in IDH-mutant non-codeleted tumours when analysed by tumour subtype. CONCLUSION: CE in low-grade gliomas provides prognostic information in IDH-mutant non-codeleted tumours, although its meaning remains uncertain in IDH-wildtype gliomas.
Authors: G Bauman; K Lote; D Larson; L Stalpers; C Leighton; B Fisher; W Wara; D MacDonald; L Stitt; J G Cairncross Journal: Int J Radiat Oncol Biol Phys Date: 1999-11-01 Impact factor: 7.038
Authors: M Klein; J J Heimans; N K Aaronson; H M van der Ploeg; J Grit; M Muller; T J Postma; J J Mooij; R H Boerman; G N Beute; G J Ossenkoppele; G W van Imhoff; A W Dekker; J Jolles; B J Slotman; H Struikmans; M J B Taphoorn Journal: Lancet Date: 2002-11-02 Impact factor: 79.321
Authors: Francesco Pignatti; Martin van den Bent; Desmond Curran; Channa Debruyne; Richard Sylvester; Patrick Therasse; Denes Afra; Philippe Cornu; Michel Bolla; Charles Vecht; Abul B M F Karim Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Abul B M F Karim; Denes Afra; Philippe Cornu; Norman Bleehan; Simon Schraub; Olivier De Witte; François Darcel; Sally Stenning; Marianne Pierart; Martine Van Glabbeke Journal: Int J Radiat Oncol Biol Phys Date: 2002-02-01 Impact factor: 7.038
Authors: Peter H Wessels; Wim E J Weber; Guy Raven; Frans C S Ramaekers; Anton H N Hopman; Albert Twijnstra Journal: Lancet Neurol Date: 2003-07 Impact factor: 44.182
Authors: Joseph F Megyesi; Edward Kachur; Donald H Lee; Magdalena C Zlatescu; Rebecca A Betensky; Peter A Forsyth; Yoshifumi Okada; Hikaru Sasaki; Masahiro Mizoguchi; David N Louis; J Gregory Cairncross Journal: Clin Cancer Res Date: 2004-07-01 Impact factor: 12.531
Authors: Michael H Lev; Yelda Ozsunar; John W Henson; Amjad A Rasheed; Glenn D Barest; Griffith R Harsh; Markus M Fitzek; E Antonio Chiocca; James D Rabinov; Andrew N Csavoy; Bruce R Rosen; Fred H Hochberg; Pamela W Schaefer; R Gilberto Gonzalez Journal: AJNR Am J Neuroradiol Date: 2004-02 Impact factor: 3.825
Authors: Antoine Girard; Pierre-Jean Le Reste; Alice Metais; Beatrice Carsin Nicol; Dan Cristian Chiforeanu; Elise Bannier; Boris Campillo-Gimenez; Anne Devillers; Xavier Palard-Novello; Florence Le Jeune Journal: J Neurooncol Date: 2021-10-22 Impact factor: 4.130
Authors: Martin Andres Merenzon; Jose Ignacio Gómez Escalante; Diego Prost; Eduardo Seoane; Alejandro Mazzon; Érica Rojas Bilbao Journal: Surg Neurol Int Date: 2022-08-05
Authors: Antoine Girard; Pierre-Jean Le Reste; Alice Metais; Nibras Chaboub; Anne Devillers; Hervé Saint-Jalmes; Florence Le Jeune; Xavier Palard-Novello Journal: Front Med (Lausanne) Date: 2021-07-09
Authors: Arthur Hosmann; Matthias Millesi; Lisa I Wadiura; Barbara Kiesel; Petra A Mercea; Mario Mischkulnig; Martin Borkovec; Julia Furtner; Thomas Roetzer; Stefan Wolfsberger; Joanna J Phillips; Anna S Berghoff; Shawn Hervey-Jumper; Mitchel S Berger; Georg Widhalm Journal: Cancers (Basel) Date: 2021-05-21 Impact factor: 6.575